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Injection-site sarcomas are considered an important entity in veterinary oncology, 
especially in cats. The current study investigated the immunohistochemical expression 
of  platelet-derived growth factor A (PDGFA), platelet-derived growth factor receptor-α 
(PDGFR-α), and integrin alpha subunit v in feline injection-site sarcomas (FISS). A total 
of  14 paraffi n-embedded tissue samples previously diagnosed as soft tissue sarcomas 
were selected from the departmental archive and sectioned at 5µm using a microtome. 
Tissue sections were stained with Hematoxylin & Eosin, Alcian blue-Periodic Acid Schiff  
(AB-PAS), Masson’s Trichrome, and immunohistochemically for PDGFA, PDGR-α, 
and integrin alpha v. The majority of  the tumors were fi brosarcomas (n=13/14), 
except one case of  myxoid liposarcoma. The tumors occurred at sites commonly used 
for injections or vaccine administration. Histologically, tumors were characterized by 
peripheral infi ltration of  mononuclear cells mainly lymphocytes, variable sized central 
necrotic areas, and many multinucleated tumor giant cells. AB-PAS staining revealed 
the presence of  myxoid or mucinous areas in (8/14) tumors while trichrome staining 
demonstrated a variable amount of  collagenous stroma in 12/14 tumors. Vimentin 
immunoreactivity was observed in all the tumors while smooth muscle actin and muscle 
actin staining was noticed in four and two cases, respectively. PDGFA and PDGFR-α 
immunoexpression was observed in all 14 cases while integrin alpha v in 13/14 cases. 
The results of  the current study indicate that fi brosarcoma is the major morphologic 
phenotype of  FISS. The PDGFA, its receptor, and integrin alpha v immunoexpression 
are increased in these tumors in cats which elucidates their role in the pathogenesis of  
FISS.
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INTRODUCTION
Injection-site sarcomas previously known as vaccine-associated sarcomas were fi rst 
described in 1991 by Hendrick and Goldschmidt and the development of  the tumor 
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was initially attributed to the administration of  vaccines (especially rabies) having 
aluminum-based adjuvants [1]. However, later advancements in the literature suggest 
that other foreign materials injected in the subcutaneous tissue or muscles can lead to 
neoplastic growth following chronic infl ammation [2]. Though most of  the injection 
site sarcomas are fi brosarcomas other tumors like malignant fi brous histiocytoma, 
osteosarcoma, rhabdomyosarcoma, chondrosarcoma, and liposarcoma have also been 
observed by some authors [3-5]. The predilection sites for FISS are the neck, thorax, 
lumbar, fl ank region, and limbs [6]. The risk for tumor development increases with 
the number of  injections at the same site [7]. Various drugs especially long-acting 
penicillin and methylprednisolone acetate [8], lufenuron an insecticide used for fl ea 
control in animals [9], suture material [10], and microchip implants [11] have also 
been mentioned as risk factors for sarcoma development in cats. Most of  the tumors 
develop between 1-3 years post-injection but may be detectable as early as 3 months 
and as late as 13-15 years [12,13]. Injection site sarcomas in the younger cats are more 
aggressive and are usually located in the subcutis and have peripheral infi ltration of  
lymphocytes. Most of  these have the myofi broblastic immunophenotype. Chronic 
infl ammation is believed to play a signifi cant role in the pathogenesis of  these FISS 
by DNA damage, cellular transformation, and clonal expansion [14]. Expression of  
matrix metalloproteinases including membrane-type matrix metalloproteinases in the 
FISS indicates the role of  infl ammation in the pathogenies of  these tumors [15]. 
PDGF expression has been implicated in the development of  soft tissue sarcomas in 
humans [16] and animals [17]. PDGFR-β expression was observed in FISS cell lines, 
non-injection site associated feline fi brosarcoma cell lines, feline fi broblast-derived 
cells line, and an in vivo tumor model exhibited expression of  PDGF-BB can protect 
tumor cells from apoptosis induced by serum starvation or doxorubicin [18,19]. In 
human non-GIST soft tissue sarcomas, the PDGFR-α expression is correlated with 
malignancy grade i.e. grade 3 tumors have higher expression compared with grade 1 
tumors and PDGFR-β has higher positivity in patients with metastasis compared with 
non-metastatic patients [20].
Integrins are heterodimeric transmembrane proteins composed of  non-covalently 
attached α and β subunits and function as to mediate cell to cell and cell to extracellular 
matrix adhesions [21]. There exist 18 α and 8 β subunits whose combinations can 
generate 24 different receptors having a different affi nity and tissue distribution [21-
23]. Integrin subunit alpha v promotes cell division, and interaction amongst neoplastic 
cells  and with extracellular matrix. It contributes in the degradation of  extracellular 
matrix by tumors cell and supports their migration within their local environment 
[24]. Consequently, alpha v integrin up-regulation at the surface of  neoplastic cells 
is frequently associated with local invasion and metastatic dissemination of  cancers 
[25,26].
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Literature is scarce about the role of  PDGFA, PDGFR-α, and integrin subunit alpha 
v in FISS. The current research highlights the clinicopathological features of  FISS and 
immunohistochemical expression of  the aforementioned molecules.
MATERIALS AND METHODS
A retrospective analysis of  feline mesenchymal tumors submitted (2004-2017) to the 
Department of  Veterinary Pathology, Faculty of  Veterinary Medicine, Ondokuz Mayis 
University Samsun, Turkey, was performed and a total of  14 feline soft tissue sarcoma 
cases were shortlisted for further examination. Formalin-fi xed paraffi n-embedded 
blocks were sectioned into 5µm thick slices using a microtome. Sections were 
deparaffi nized as per standard histological procedure and stained with hematoxylin 
and eosin. The diagnosis of  the tumors was reviewed after histological analysis and 
subsequent immunolabelling. Histological grading of  the tumors was done by following 
the criteria described for soft tissue sarcomas by Federation Nationale des Centers 
de Lutte Contre le Cancer (FNCLCC) for humans, but is also widely accepted in 
animal oncology [25,26]. The tumors were graded based on the mitotic rate, presence 
or absence of  necrosis, and degree of  differentiation (Table 1). Mitotic count was 
determined in an area of  2.37mm2 at 40x (10 high power fi eld) by using a microscope 
assembled with an ocular of  fi eld number (FN) 22 mm [27].
Table 1. Criteria used for grading soft tissue sarcomas
Degree of  Differentiation
Score 1: Tumor cells are well differentiated and show high resemblance to 
adult mesenchymal tissue e.g. well-differentiated liposarcoma
Score 2: Sarcomas for which histologic type is certain e.g. myxoid 
liposarcoma
Score 3: Embryonal and poorly differentiated sarcoma 
Mitotic Count:
Score 1: 0-9 mitotic fi gures in an area of  2.37mm2
Score 2: 10-19 mitotic fi gures in an area of  2.37mm2
Score 3: more than 20 mitotic fi gures in an area of  2.37mm2
Tumor necrosis: Score 0: No necrosisScore 1: Less than 50% of  tumor has necrosis
Score 2: More than 50% of  tumor has necrosis
Histological grade: Grade 1: Total score 2, 3Grade 2: Total score 4,5
Grade 3: Total score 6, 7, 8
Histochemi cal stains
Masson’s trichrome stain and Alcian blue/Periodic acid Schiff  (AB-PAS) were used for 
the evaluation of  various stromal components of  tumor tissues. Masson’s trichrome 
staining was performed for the evaluation of  collagen as described by Jones et al. [28] 
and was graded 1 for very mild staining of  the stromal tissue, 2 for moderate, and 3 
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for fair positivity. AB-PAS staining was carried out as per the method of  the Mowry 
[29,30] for the evaluation of  mucopolysaccharides.
Immunohis tochemistry 
The formalin-fi xed paraffi n-embedded tissue sections were subjected to immuno-
histochemical staining using the streptavidin-biotin peroxidase method [31]. The 
details of  the antibodies used are presented in Tables 2 & 3. 
Table 2. Panel of  antibodies used for histogenic characterization of  tumors 
Antibody Dilution Host/isotype/immunogen Source & product codes
Myoglobin 1:10000 Rabbit, PAb*, IgG, Human Abcam, ab74213
Alpha sarcomeric 
actinin 1:10000 Mouse, MAb†, IgG1, rabbit Sigma Aldrich, A7811
Alpha smooth 
muscle actin 1:10000 Mouse, MAb, IgG2akappa Thermo, MS-113-P
Desmin 1:10000 Mouse, MAb, IgG2b, Chicken Santa-Cruz, sc-23879
Myogenin 1:50 Mouse, MAb, IgG1 Kappa MGN185(F5D), NBP2-29431
MyoD1 1:50 Mouse, MAb, IgG1 Kappa NB100-56511, Novus Biologicals
Muscle specifi c 
actin Ready to use Mouse, Mab, IgG1 kappa Neomakers, Ab-4, MS-742-R7
Vimentin 1:10000 Mouse, MAb, IgG2a, Bovine Abcam, ab28028
S-100 1:10000 Mouse, MAb, IgG2a, Bovine Thermo, MS-296-P
GFAP 1:4000 Mouse, MAb, IgG1 Merck Millipore, MAB3402
*PAb; Polyclonal antibody, †Mab; Monoclonal Antibody
Table 3. Details of  the antibodies used to study the immunoexpression of  PDGFA, PDGFR-α, 
and integrin alpha v
Antibody Dilution Host/Isotype/Immunogen Source & Product codes
Integrin alpha v 1:500 Rabbit, PAb*, IgG, Merck: AB1930
PDGFA 1:100 Mouse, MAb†, IgG1 Santa Cruz (E-10): sc-9974
PDGFR-α 1:400 Rabbit, PAb, IgG, Santa Cruz (C-20): sc-338
*PAb; Polyclonal antibody, †MAb; Monoclonal antibody
Briefl y, the serial sections were rinsed with distilled water after processing in xylene 
and graded levels of  alcohol. Following this, a 3% solution of  hydrogen peroxide 
in absolute methanol was used to block the activity of  endogenous peroxidase for 
10 minutes. After rinsing with phosphate-buffered saline (PBS, pH 7.4), the tissue 
sections were subjected to antigen retrieval using citrate buffer (pH 6.0) in a microwave 
oven (600 W) for 10 min. A ready to use commercially available blocking solution 
Ishtiaq and Sozmen: Expression of  platelet derived growth factor A, its receptor, and integrin subunit alpha v in feline injection-site sarcomas
17
(Zymed Laboratories, Inc.; San Francisco, CA, USA) was used for 10 minutes (at room 
temperature) to block nonspecifi c binding of  the secondary antibody. Sections were 
washed with PBS and then incubated with each of  the primary antibodies for 1-2 hours 
at room temperature. A brief  rinsing of  sections with PBS 2-3 times was followed 
by incubation with a biotin-conjugated secondary antibody for 20 minutes at room 
temperature (Zymed Laboratories). Later, sections were washed with PBS and treated 
with streptavidin-biotin-peroxidase complex (SABC, Zymed Laboratories) for 20 
minutes at room temperature in a humidifying chamber. After brief  rinsing with PBS 
signals were visualized using 3-amino-9-ethylcarbazole (AEC substrate kit; Invitrogen, 
Camarillo, Canada) as a chromogen. A counterstaining with Harris hematoxylin 
was performed for 1 minute, rinsed with running tap water, and mounted with an 
aqueous mounting medium (Vision Mount; Lab Vision, USA). Primary antibodies 
were omitted from negative control sections, which were incubated with either PBS 
or diluted normal serum from the species in which the primary antibody was raised.
Evaluation of immunostaining
A semiquantitative approach was used to evaluate the immunolabeling of  various 
antibodies. The percentage of  the positive cells and intensity of  staining were taken into 
consideration during the evaluation and a score between 0-300 was given depending 
on both factors. H-score (Histological score) was calculated by the formula 1x (% cells 
weak positive), +2x (% cells moderately positive), +3x (% cells strong positive). 
Statistical analysis
GraphPad Prism® 5 was used for the statistical analyses of  the data. Mitotic count 
between tumor grades were compared by Mann-Whitney test. The data (H-score) 
obtained from the immunohistochemical analysis of  different grades of  tumors was 
analyzed by descriptive statistics and also compared for the difference in their median 
values by using the Kruskal Wallis test. P < 0.05 was considered signifi cant.
Informed c onsent: Informed consent has been obtained for client-owned animals 
included in this study.
RESULTS
Clinicopath ological fi ndings
The majority of  the tumors were fi brosarcomas (n=13/14), except for one case of  
myxoid liposarcoma (Table 4). The tumors included in this study occurred at the sites 
commonly used for injections or vaccine administration. No information was available 
about the use of  any vaccine or drug. The age range of  the cats varied from fi ve to 
13 years (median 9.5 years). Seven of  the cats were male and fi ve were female while 
gender information was missing about two cats. 
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9 M Interscapular Fibrosarcoma 1 2 2 2
NA NA Interscapular Fibrosarcoma 2 1 1 2
5 M Back/Dorsum Fibrosarcoma 1 2 2 2
10 M Right gluteal Fibrosarcoma 1 2 1 2
11 F Left thoracic Fibrosarcoma 2 1 2 2
9 M Back/Dorsum Fibrosarcoma 1 1 2 2
NA NA Dorsolumbar Fibrosarcoma 1 1 2 2
13 M Interscapular Myxoid Liposarcoma 2 1 2 2
12 F Dorsal region Fibrosarcoma 2 1 2 2
10 M Scapular region Fibrosarcoma 2 1 2 2
12 F Interscapular Fibrosarcoma 3 2 2 3
6.5 M Left thoracic Fibrosarcoma 3 2 2 3
9 F Left thoracic wall Fibrosarcoma 3 1 2 3
8 F Subcutaneous nodule Fibrosarcoma 3 1 3 3
M: Male, F: Female, NA: Not available, *Mitotic count was determined in an area of  2.37mm2 at 
high-power fi eld (40x objective); low (1) = 0-9, moderate (2) = 10-19 or high (3) = >20; †(1) well 
differentiated, (2) moderately differentiated, (3) poorly differentiated
The tumors were located beneath the dermis. A pseudocapsule was observed in a few 
cases. Peripheral foci of  lymphocytic infi ltration were noticed (Figure 1a). However, 
histiocytic cells or macrophages were scant in the cases studied (observed in three 
cases). The tumor cells were comprised of  mesenchymal spindle-shaped cells. Most 
of  the tumors had anaplastic features with the presence of  multinucleated cells while 
classical herringbone pattern was rarely observed (Figure 1b, 1c). Variably sized areas 
of  necrosis were also present (Figure 1a). Mitotic index was signifi cantly higher in 
grade 3 tumors in comparison with grade 2 tumors (P<0.05). 
Mucin containing areas were observed in some of  the tumors. The myxoid liposarcoma 
was composed of  cells with a peripheral nucleus having a vacuolar cytoplasm (Figure 
2). Neoplastic cells exhibited marked anisocytosis and anisokaryosis. Many giant 
cells were scattered through the tumor stroma. Staining with AB-PAS showed mucin 
secretion in the myxoid areas leading to the diagnosis of  myxoid liposarcoma (Figure 3).
Histochemical analysis of tumors 
Myxoid or mucinous areas stained positive in 8/14 tumors with AB-PAS staining while 
12/14 tumors showed mild to fair staining of  the stromal collagen with trichrome 
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stain, four tumors in each category i.e. 1, 2, and 3, and two tumors were negative 
(Table 5). 
Immunohistochemical staining 
Vimentin reactivity was observed in all the tumors (Figure 4). Four tumors showed 
smooth muscle actin positivity at the periphery and two for muscle actin. A focal 
area of  mild myoglobin reactivity was noticed in one case (tumor no: 12) which was 
Figure 1. a: Photomicrograph of  an injection site fi brosarcoma from a cat. Note the 
peripheral foci of  infl ammatory cells (asterisks), tumor cells (arrowhead), and necrotic areas 
(star), b: A grade 2 fi brosarcoma with peripheral lymphocytic infi ltration (asterisk). c: A highly 
anaplastic grade 3 fi brosarcoma with many multinucleated tumor giant cells (arrows) inset: high 
magnifi cation view of  tumor giant cell. H&E. Bar, a, 300 µm; b & c, 150 µm.
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categorized as injection-site sarcoma. GFAP, S100, desmin, muscle actin, sarcomeric 
actin, myoglobin, myogenin, and myoD1 were negative. 
Figure 2. Photomicrograph of  a myxoid liposarcoma showing neoplastic cells with cytoplasmic 
vacuolation pushing the nucleus to the periphery of  the cell. H&E. Bar,30 µm. 
Figure 3. AB-PAS staining of  myxoid liposarcoma showing mucinous matrix. Bar,30 µm. 
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*Trichrome staining: + (Very low amount of  collagenous stroma), ++ (Mild to moderate collagenous 
stroma), +++ (Fair amount of  collagenous stroma).
Figure 4. Cytoplasmic immunoreactivity for the vimentin antibody from an injection-site 
fi brosarcoma of  a cat. IHC. Bar,30 µm. 
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PDGFA and PDGFR-α
Cytoplasmic PDGFA expression was noticed in neoplastic cells in all the tumors 
(Figure 5). Other than tumor cells, remnants of  muscle cells, blood vessel walls, and 
epithelium of  hair follicles showed positive reactivity for PDGFA. Histiocytic cells 
with cytoplasmic immunoreactivity were noticed in a few cases. Though grade 3 
tumors showed relatively higher PDGFA expression than grade 2 tumors, statistically 
this difference was non-signifi cant.
Figure 5. PDGFA immunoreactivity in an injection-site fi brosarcoma of
a cat. IHC. Bar, 30 µm.
Figure 6. Neoplastic cells of  a feline injection-site sarcoma showing
nuclear and cytoplasmic staining for PDGFR-α. IHC. Bar, 30 µm. 
Ishtiaq and Sozmen: Expression of  platelet derived growth factor A, its receptor, and integrin subunit alpha v in feline injection-site sarcomas
23
PDGFR-α expression was observed in 14/14 tumors (Figure 6). Tumor cells showed 
both nuclear and cytoplasmic staining for PDGFR-α. A variable staining reaction was 
observed in peripheral lymphocytes and macrophages for PDGFR-α. Other than 
tumor cells, blood vessels and muscles were also positive for PDGFR-α. Numerical 
scoring of  PDGFR- α expression was relatively high in grade 2 tumors in comparison 
with grade 3 tumors, however, there was no statistically signifi cant difference. The 
semiquantitative analysis of  immunoreactivity score is given in Table 6.  
Table 6. Comparison of  H-score of  Integrin alpha v, PDGFA, and PDGFR-alpha in feline 
fi brosarcoma
Tumor Grade Integrin alpha v PDGFA PDGFR
2 88.33 ± 18.31 108.4 ± 24.91 121.4 ± 19.95
3 112.5 ± 33.82 140.0 ± 24.15 78.2 5± 29.01
Data presented as Mean ± SEM, p>0.05, H-score did not show any signifi cant difference between 
different grades of  tumors in cats
Integrin alpha v
Membranous, as well as cytoplasmic staining was observed in most of  the tumors 
(n=13/14) as shown in Figure 7. Multinucleated tumor giant cells and normal skeletal 
muscle cells also showed cytoplasmic reactivity for the integrin alpha v. However, 
infi ltrating lymphocytic foci were negatively stained. Neoplastic cells in grade 3 FISS 
revealed a higher immunoreactivity than grade 2 tumors, however, statistically, this 
difference was not signifi cant. The mean score of  the immunoreactivity of  integrin 
alpha v is presented in Table 6. 
Figure 7. Integrin alpha v expression in a grade 3 injection-site
fi brosarcoma of  a cat. IHC. Bar, 30 µm.  
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DISCUSSION
Injection-site sarcomas are believed to originate in response to the injection of  
foreign materials in any animal species especially cats. In the current study, 13 cases 
of  fi brosarcomas and one myxosarcoma were observed at the anatomical sites used 
for injections or vaccine administration in cats. As observed in the current study 
fi brosarcoma is the most common histological variant occurring at the injection sites 
in cats, although reports of  other tumors e.g. chondrosarcoma, rhabdomyosarcoma, 
osteosarcoma, and liposarcoma do exist [3,4,32]. Generally, injection site fi brosarcoma 
is of  moderate to high-grade invasive tumors [33,34]. We observed grade 2 (n=10) and 
grade 3 (n=4) tumors in cats and it was in partial agreement with Couto et al. [35], 
who reported a higher number of  grade 2 (47.7%) and grade 3 (27.3%) fi brosarcomas 
along with 25% grade 1 tumors. 
Histological examination of  the tumors revealed a subcutaneous location of  tumors 
with peripheral lymphocytic infi ltration and few histiocytes. This feature has been 
consistently observed since the very fi rst reports of  the injection site sarcomas and 
is considered pathognomonic for diagnosis [3,7,32,33,36,37]. Previous studies also 
reported the presence of  macrophages with engulfed foreign material (aluminum-
based adjuvant used in the vaccine), but it was not a predominant feature in our study. 
But it is not a mandatory feature of  all the FISS as Couto et al. [35] observed large 
foamy macrophages in only 22.5% and 25% of  primary and recurrent fi brosarcomas, 
respectively. Moreover, there have been reports of  feline fi brosarcomas at the presumed 
injection site with infl ammatory reaction without foamy macrophages [34,38,39]. The 
presence or absence of  the macrophages with intracytoplasmic basophilic granular 
material may be related to the presence or absence of  adjuvants in the vaccine [34]. The 
persistence of  infl ammatory cells is a major factor contributing to the pathogenesis of  
injection-site sarcomas [14,40,41]. 
Tumor cells were pleomorphic to spindle-shaped with a lack of  characteristic 
herringbone pattern of  fi brosarcomas. Multinucleated giant cells are another 
histological characteristic of  FISS [34,35] which were also recorded in the present 
study. Tumor samples from eight cats demonstrated myxomatous/ mucin containing 
areas with loosely arranged spindle-shaped or stellate cells. Injection site sarcomas 
with myxomatous matrix were also observed in previous studies and injection site 
sarcomas have a greater tendency to produce myxomatous stroma as compared to 
non-injection site feline sarcomas [37,42]. As observed in previous studies, mitotic 
count was signifi cantly high in grade 3 tumors as compared to grade 2 tumors. High 
mitotic rate indicates rapid proliferation of  neoplastic cells and therefore is a feature 
of  fast growing aggressive tumors [39,43]. 
All the tumors in this study showed no reactivity for desmin and were positive for 
vimentin. This fi nding is in agreement with the previous studies [35]. One sample 
of  cats showed reactivity to muscle actin and alpha-smooth muscle reactivity was 
noticed in 4/14 tumors of  cats. This number is quite low as compared to previous 
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studies (28/44) [35], (7/10) [34]. Smooth muscle reactivity indicates the presence of  
myofi broblasts in the tumors which are considered a transitory phase through which 
fi broblasts and macrophages pass during wound healing [2]. Though their precise role 
in ISSs is unclear[44], some authors describe it as an atypical response to traumatic 
injury [2].
Desmin, S-100, sarcomeric actinin, pan-cytokeratin, GFAP, myogenin, and myoD1 
were negative in the current study. One case showed focal reactivity to myoglobin and 
two for muscle actin. Previously, S-100 positivity was observed in a chondrosarcoma 
at the injection site but not in fi brosarcoma [3]. Myoglobin reactivity in one animal 
in the current study may indicate regenerating muscle cells in the areas invaded by 
tumor cells. Myogenin and myoD1 are highly specifi c and sensitive markers for tumors 
showing skeletal muscle differentiation [45]. Negative reactions to these antibodies in 
all feline tumors helped in the exclusion of  rhabdomyosarcomatous differentiation in 
the tumors under study.
PDGF/PDGFRs axis plays an important role in the pathogenesis of  many humans 
and animal tumors including soft tissue sarcomas[17]. Upregulation of  PDGFA and 
its receptor alpha was present in all the (100%) tumors. Other than tumor cells, muscle 
cells, blood vessel walls and epithelium of  hair follicles showed positive reactivity. 
The results of  the current study are partially in line with the previous reports of  the 
immunoreactivity of  PDGF and its cognate receptor in feline injection-site sarcomas 
[46]. Hendrick [46] also reported the immunopositivity of  peripheral lymphocytes and 
macrophages and strong staining in the tumor cells near these infl ammatory cells which 
were partially observed in the current study. The difference may be due to the use of  
antibodies against a different isoform of  PDGF and PDGFR. The two other studies 
investigating the role of  PDGF/PDGFRs axis in FISS were carried out targeting 
PDGF-BB and PDGFR-β but not α [18,19]. They used FISS cell lines and a xenograft 
murine tumor model and evaluated imatinib [18] and masitinib [19] anti-tyrosine 
kinase drugs to inhibit tumor cell growth by blocking the expression of  PDGFR-β. 
However, in human medicine, co-expression of  PDGFR-α and its ligands has been 
implicated in several tumors and an anti-PDGFR-α antibody named olaratumab is 
being evaluated as a therapeutic candidate [47]. The PDGFA and PDGFR-α expression 
was not signifi cantly different between grade 2 and grade 3 tumors. Literature is scarce 
about correlation between histological grades and PDGFA/PDGFR-α expression in 
FISS. PDGFA/PDGFR-α expression may vary amongst different histological grades 
and types of  tumors. A positive correlation between histological grades, proliferative 
index and PDGFA/PDGFR-α expression was observed in soft tissue sarcomas in 
humans[20] while oligodendrogliomas and meningiomas only showed this correlation 
for PDGFA and not for PDGFR-α expression [48,49]. 
Integrin alpha v binds to vitronectin and fi bronectin which are its principal ligands and 
contribute to local invasion and distant spread of  the neoplastic cells [50]. The role of  
integrin alpha v is well established in several human cancers e.g. melanoma, breast, and 
pancreatic tumors [51-53]. Integrin alpha v expression was observed in 93% of  the 
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tumor samples. Literature is scarce on the role of  integrin alpha v expression in FISS 
and we fi nd only one previous report describing the expression of  integrin alpha vβ3 in 
the tumors that authors described as “highly infi ltrative spontaneous fi brosarcomas”. 
The main objective of  the study was to test a NIR-dye labeled nanoprobe targeting 
the integrin alpha vβ3 in the near-infrared optical guided excision of  the tumors. They 
observed integrin expression on the endothelial cells and the surface of  the tumor 
cells in the proximity of  the blood vessels[54]. Our results are in partial agreement 
with the fi ndings of  the aforementioned study. However, it is not clear whether the 
enrolled subjects in the previous study were having spontaneous fi brosarcoma or 
injection-site fi brosarcoma as the pathogenesis of  both is different. Furthermore, the 
authors described the positive staining in the vascular endothelium and tumor cells in 
the vicinity of  the vessels, but we observed a widespread staining reaction throughout 
the tumor tissue, including multinucleated tumor cells, and normal skeletal muscles. 
A high immunoexpression was observed in grade 3 tumors as compared to grade 2 
tumors. Similar fi ndings have been reported in human gliomas [55]
In conclusion, the FISS continues to be an important malignancy in cats and 
fi brosarcoma is the predominant histological phenotype in cats. PDGFA, PDGFR-α, 
integrin alpha v immunoexpression is considerably increased in FISS. This explains 
the possible role of  these molecules in the pathogenesis of  FISS. However, further 
studies involving large cohorts of  animals and focusing on other adhesion molecules, 
growth factors, and angiogenic factors may help in a better understanding of  tumor 
progression and identifi cation of  a precise target for chemotherapy. 
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EKSPRESIJA FAKTORA RASTA TROMBOCITA, NJIHOVIH 
RECEPTORA KAO I SUBJEDINICE ALFA INTEGRINA U 
POSTVAKCINALNIM SARKOMIMA MAČAKA NA MESTU 
INJEKCIJE
ISHTIAQ Ahmed, SOZMEN Mahmut
Smatra se da su sarkomi na mestu injekcije značajan patološki entitet u veterinarskoj 
onkologiji, naročito kod mačaka. Studija je ispitivala imunohistohemijsku ekspresiju 
faktora rasta A, poreklom iz trombocita (PDGFA), receptora za faktor rasta – alfa 
poreklom iz trombocita (PDGRF-α) i integrin alfa subjedinice v u slučajevima 
sarkoma na mestu inokulacije (FISS). Ukupno je ispitano 14 parafi nskih uzoraka, 
poreklom od prethodno dijagnostikovanih sarkoma mekih tkiva, iz podataka arhive 
departmana. Uzorci su standardno obrađeni i isečeni na isečke debljine od 5 µm 
pomoću mikrokriotoma. Uzorci tkiva su bojeni standardnom hematoksilin-eozin, 
Alcian plavo-Periodic Acid Schiff  (AB-PAS) i Mason-trihrom tehnikama bojenja kao 
i imunohistohemijski u cilju detekcije PDGFA, PDGR-α kao i integrin-alfa v. Većina 
tumora su po svojim karakteristikama bili fi brosarkomi (n=13/14), osim u jednom 
slučaju miksoliposarkoma. Tumori su bili locirani na uobičajenim mestima inokulacije 
vakcina. Histološki u tumorima je uočena  infi ltracija mononuklearnim ćelijama, 
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većinom limfocitima, a u centralnim regionima nekrotična područja promenljive 
veličine, i prisustvom većieg broja multinuklearnih gigantocita. AB-PAS bojenjem, 
uočeno je prisustvo miksoidnih ili mucinoznih regiona kod 8 od 14 tumora dok je 
trihrom bojenje ukazalo na varijabilnu količinu kolagene strome kod 12 od ukupno 
14 tumora. Kod svih tumora, uočena je imunoreaktivnost na vimentin, pri čemu 
je reaktivnost na glatkomišični aktin  uočena kod četiri, odnosno kod dva slučaja. 
Imunoekspresija PDGFA kao i PDGFR-α zapašena je u svih 14 slučajeva pri čemu je 
pozitivan nalaz na integrin alfa bio u 13 od 14 slučajeva. Rezultati studije ukazuju da je 
morfološki fenotip FISS prevashodno u tipu fi brosarkoma. PDGFA, njegovi receptori 
i ekspresija integrin alfa v su povećani u slučaju ovih tumora mačaka, što ukazuje na 
njihovu ulogu u patogenezi FISS. 
